+ Filter
Loading...
Custom Services order now ship next day

CD37

Loading...

Anti-CD37 Products

    • Target: CD37
    • Linker: SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
    • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto- 1-oxopropyl)maytansine)
    Go to compare Compare
    • Target: CD37
    • Linker: SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
    • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
    Go to compare Compare
    • Target: CD37
    • Linker: VC (Valine-citrulline)
    • Drug: MMAE (monomethyl auristatin E)
    Go to compare Compare
More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs offers high-quality, comprehensive recombinant antibodies specifically targeting CD37, designed to meet the needs of biomedical researchers and institutions. Our antibodies are meticulously developed to ensure optimal specificity and performance in various applications. With a commitment to advancing research, we provide reliable tools that empower scientists to make significant discoveries in their respective fields, enhancing the overall impact of their work.

CD37: A Significant Target in Hematological Malignancies

CD37 is a transmembrane protein expressed on the surface of various immune cells. It plays a crucial role in regulating immune responses and cell signaling. In the context of diseases, CD37 is of significant interest, particularly in hematological malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The abnormal expression of CD37 in these cancers makes it an attractive therapeutic target. Clinical research on targeting CD37 has shown great potential. For instance, monoclonal antibodies or antibody-drug conjugates directed against CD37 have demonstrated efficacy in clinical trials. They can selectively target and kill cancer cells expressing CD37, offering a novel treatment approach with reduced side effects compared to conventional therapies. Moreover, understanding the role of CD37 in disease progression and its interaction with the tumor microenvironment could lead to the development of more effective combination therapies, improving patient prognosis and quality of life.

Alternative Names

CD37 molecule, GP52-40, TSPAN26

Background

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is a cell surface glycoprotein that is known to be complex with integrins and other transmembrane 4 superfamily proteins. It may play a role in T-cell-B-cell interactions. Alternate splicing results in multiple transcript variants encoding different isoforms.

Protein class

CD markers

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Cell type enhanced (B-cells, dendritic cells, NK-cells, T-cells, monocytes, Langerhans cells, Hofbauer cells, Macrophages)

Immune cell specificity

Low immune cell specificity

Cell line specificity

Cell line enhanced (Daudi, HMC-1, RPMI-8226, THP-1, U-698, U-937)

Interaction

Interacts with SCIMP.

More Types Infomation

Anti-CD37 rAb Products

The high-quality anti-CD37 recombinant antibody products are furnished to accelerate the research and discovery of drugs associated with the target CD37.

Cat. No. Product Name Target Species Host Species Applications
TAB-904 Anti-Human CD37 Recombinant Antibody (Otlertuzumab) Human Human ELISA; IP; FC; FuncS; Neut; IF; ICC
TAB-0272CL-S(P) Anti-Human CD37 Recombinant Antibody scFv Fragment (chHH1.1) Human Human ELISA; WB
HPAB-0159-FY Mouse Anti-CD37 Recombinant Antibody (HPAB-0159-FY) Human Mouse Activ; Depletion; FuncS
HPAB-AP033-YC Human Anti-CD37 Recombinant Antibody (clone A2) Human Human FuncS
HPAB-1047-FY Human Anti-CD37 Recombinant Antibody Human Human ELISA; FC; IHC

Creative Quality Control

To meet the demands of our customers regarding antibody quality, a strict quality management system has been set up to guarantee our product quality and assist customers in conducting research work more effectively.

Fig.1 SDS-PAGE analysis of TAB-0272CL-S(P). (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CD37 antibody (Cat#
TAB-0272CL-S(P), Creative Biolabs).

Fig.2 SEC-HPLC analysis of TAB-0272CL-S(P). (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CD37 antibody (Cat# TAB-0272CL-S(P), Creative Biolabs).

Customer Reviews

Excellent
Ca**y
Anti-Human CD37 Recombinant Antibody scFv Fragment (chHH1.1) (Cat#: TAB-0272CL-S(P))
I employed the anti-human CD37 recombinant antibody scFv fragment (chHH1.1) in my research on certain blood disorders. I utilized the ELISA method for detection. The results were remarkable. This antibody precisely identified the CD37 markers, providing highly accurate and consistent data. It proved to be an invaluable tool, significantly enhancing the credibility and progress of my study, and enabling a deeper exploration of the role of CD37 in the context of the investigated disorders.
23/Feb/2022
Excellent
Cr**t
Anti-Human CD37 Recombinant Antibody (Otlertuzumab) (Cat#: TAB-904)
The anti-human CD37 Recombinant Antibody (Otlertuzumab) was purchased in my research on lymphoma. I chose flow cytometry for detection and the results were excellent. This antibody precisely identified the CD37 molecules on the surface of cancer cells, providing highly accurate and reliable data. It greatly facilitated my study and deepened my understanding of the role of CD37 in lymphoma progression.
15/May/2023
Excellent
Sh**y
Human Anti-CD37 Recombinant Antibody (Cat#: HPAB-1047-FY)
This anti-human CD37 recombinant antibody was used in my research on certain hematological disorders. To detect it, I adopted immunohistochemistry, and the outcome was outstanding. This antibody accurately identified the expression of CD37 in the tissue samples, offering distinct and reliable data. Not only that, but its stability is also remarkable, making it very convenient and reliable to handle.
8/Jul/2023

Anti-CD37 Recombinant Antibody Production

Our serum-free mammalian cell expression platform provides a one-stop service, which extends from gene synthesis to the production of high-quality milligram recombinant antibodies. We have over 5 years of experience in optimizing processes related to expression vectors, cloning systems, and high-yield mammalian cell lines, and can supply customers with high-quality and stable antibodies.

Featured Anti-CD37 Recombinant Antibody Production PlatformsFig.3 Milligram-scale anti-CD37 recombinant antibody production. (Creative Biolabs Original)
Fig.3 Milligram-scale recombinant antibody production.

Fig.4 Gram-scale anti-CD37 recombinant antibody production. (Creative Biolabs Original)Fig.4 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs is determined to supply researchers with the most all-round and state-of-the-art high-quality recombinant antibodies in diverse formats. The antibody formats comprise, without limitation, full length, scFv, scFv-Fc, scFv-CH3, sc-Fab, full length with various Fc isotypes, etc. Our products are supported by superior custom engineering services in accordance with your specific requirements.

Fig.5 Full Length Anti-CD37 Recombinant Antibody Production and Modalities. (Creative Biolabs Original) Fig.5 Full Length Anti-CD37 Recombinant Antibody Production and Modalities

Drug Information Targeting CD37

Table 1. Therapeutic approaches targeting CD37 in clinical development.

Research phase Company Classification Indications Details
Phase II Debiopharm Drug Conjugates Chronic lymphocytic leukemia; Cancer It is an antibody-drug conjugate (ADC) originated at ImmunoGen consisting of the CD37-binding, humanized IgG1antibody K7153A attached to the maytansinoid DM-1 via the non-cleavable thioether linker SMCC.
Phase II Abbott
Aptevo Therapeutics
Biologics Autoimmune disease;
Chronic lymphocytic leukemia
It is a CD37-targeted therapy in phase II clinical trials at Aptevo Therapeutics (spun-out from Emergent Biosolutions) for the treatment of peripheral T-cell lymphoma. Phase I/II clinical trials are also underway for the treatment of chronic lymphocytic leukemia (CLL).

If you need more information regarding our anti-CD37 recombinant antibody products, feel free to reach out to us at any time. Our team is eager to assist you with any questions or inquiries, and we look forward to developing a mutually beneficial collaboration that advances your research efforts.

Go to compare

Go to compare